Drug Profile
KM 8399
Alternative Names: Anti-hIL-5R MoAbLatest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator Kyowa Hakko Kirin
- Developer Kyowa Kirin
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
- 26 Jun 2004 This compound is still in active development
- 31 Oct 2002 Preclinical trials in Asthma in Japan (Parenteral)